Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Director of DPUK © DPUK

For no personal gain, health study volunteers have consented to health tests and lifestyle questions – often over a number of decades. Some health studies now grant access to these data through the Dementias Platform UK (DPUK) – the richest single source of dementia focussed health study data. Protecting this valuable data demands the highest standards of privacy and security.  To this end, personal data is stripped out so that individuals cannot be identified and data are managed according to ISO 27001 standards. Researcher can only access the data through a secure online environment, which prevents data being downloaded.

Professor John Gallacher, Director of DPUK, said ‘Long-term health data is really important for two reasons.  Firstly, it helps us identify the patterns of change or decline in healthy brains because this is how science will discover how dementia starts. Secondly, it helps us pinpoint the right volunteers for targeted dementia trials to help develop new treatments. Dementia starts up to 20 years before the first symptoms show and just like cancer we need to find out how to treat it early, before the disease does substantial damage’. 

Without the data from health study volunteers, researching and developing preventative treatments will take decades. The value of health study volunteers is that their data already exists and we can take advantage of this now in searching for new treatments.

We need health studies participants to volunteer for clinical trials if we are to speed up the discovery of preventative treatments for dementia. At the end of 2018, DPUK will launch a clinical studies register that recruits health study volunteers for a new generation of targeted clinical trials. As with all DPUK endeavours, this will work to highest standards of privacy and security. Participants can choose whether they wish to join, and make their own decisions about the type of trials they would be willing to support.

On World Alzheimer's Day it’s important to recognise the generosity of cohort volunteers who contribute data to DPUK cohorts. DPUK is helping researchers accelerate the development of treatments for dementia.
- John Gallacher, DPUK Director

Similar stories

Comment: COVID has exposed the need for flexible global data access

At a time when the work of disease modellers has been thrust into the spotlight, DPUK’s director, Professor John Gallacher, comments on the important role of technology platforms which democratise access to global health data.

Dementia Ecosystem UK: action through alliance

One in three people born today will develop dementia in their lifetime: it's the biggest health challenge of our generation. With one million people predicted to have dementia by 2025 in the UK, and a current cost of £26bn a year to the UK economy, there is huge financial and societal impact, yet we’re still without treatment.

Cohorts invited to join dementia trials register

DPUK has launched Great Minds, an innovative new register of volunteers for clinical trials who bring rich data from their previous health studies to help clear the deadlock in development of treatments for dementia.

Datathon for dementia

Data scientists from many different backgrounds combined their expertise to take on dementia in an unusual format for disease research: a three-day datathon. The intensive research event saw teams come together to work on data that is now available in the DPUK Data Portal.

DPUK approach attracts interest from beyond dementia sector

Thanks to leaps forward in computing power, DPUK is able to harness highly advanced technical solutions to maintain data security and non-identifiability of millions of existing health records in the Data Portal. It’s a model that is globally unique for dementia research and one that’s increasingly attracting attention from other sectors.

New partner announcement: Cambridge Cognition

Dementias Platform UK continues to expand as Cambridge Cognition, a global leader in cognitive assessment for clinical trials, upgrades its current position as associate partner to become full partner.